BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27154293)

  • 1. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
    Pietrantonio F; Berenato R; Maggi C; Caporale M; Milione M; Perrone F; Tamborini E; Baratti D; Kusamura S; Mariani L; Niger M; Mennitto A; Gloghini A; Bossi I; Settanni G; Busico A; Bagnoli PF; Di Bartolomeo M; Deraco M; de Braud F
    J Transl Med; 2016 May; 14(1):125. PubMed ID: 27154293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward the molecular dissection of peritoneal pseudomyxoma.
    Pietrantonio F; Perrone F; Mennitto A; Gleeson EM; Milione M; Tamborini E; Busico A; Settanni G; Berenato R; Caporale M; Morano F; Bossi I; Pellegrinelli A; Di Bartolomeo M; de Braud F; Baratti D; Bowne WB; Kusamura S; Deraco M
    Ann Oncol; 2016 Nov; 27(11):2097-2103. PubMed ID: 27502722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin.
    Ghelardi F; Raimondi A; Morano F; Randon G; Pannone A; Guaglio M; Mazzoli G; Nasca V; Milione M; Leoncini G; Sabella G; Greco GF; Lampis BR; Galassi M; Delfanti S; Nannini M; Intini R; Baratti D; Di Bartolomeo M; Deraco M; Pietrantonio F
    Clin Colorectal Cancer; 2023 Dec; 22(4):450-456.e1. PubMed ID: 37657955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei.
    Raimondi A; Corallo S; Niger M; Antista M; Randon G; Morano F; Milione M; Kusamura S; Baratti D; Guaglio M; Cremolini C; Marmorino F; Di Bartolomeo M; Deraco M; De Braud F; Pietrantonio F
    Clin Colorectal Cancer; 2019 Jun; 18(2):e179-e190. PubMed ID: 31023524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biological basis and function of GNAS mutation in pseudomyxoma peritonei: a review.
    Lin YL; Ma R; Li Y
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2179-2188. PubMed ID: 32700107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.
    Nummela P; Saarinen L; Thiel A; Järvinen P; Lehtonen R; Lepistö A; Järvinen H; Aaltonen LA; Hautaniemi S; Ristimäki A
    Int J Cancer; 2015 Mar; 136(5):E282-9. PubMed ID: 25274248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.
    Pietrantonio F; Maggi C; Fanetti G; Iacovelli R; Di Bartolomeo M; Ricchini F; Deraco M; Perrone F; Baratti D; Kusamura S; Tamborini E; Castano A; Consonni PV; Bossi I; Gavazzi C; Milione M; Pelosi G; de Braud F
    Oncologist; 2014 Aug; 19(8):845-50. PubMed ID: 24951608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and clinicopathological features of appendiceal mucinous neoplasms.
    Yanai Y; Saito T; Hayashi T; Akazawa Y; Yatagai N; Tsuyama S; Tomita S; Hirai S; Ogura K; Matsumoto T; Wada R; Yao T
    Virchows Arch; 2021 Mar; 478(3):413-426. PubMed ID: 32821969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
    Choe JH; Overman MJ; Fournier KF; Royal RE; Ohinata A; Rafeeq S; Beaty K; Phillips JK; Wolff RA; Mansfield PF; Eng C
    Ann Surg Oncol; 2015 Aug; 22(8):2578-84. PubMed ID: 25582740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
    Tan GH; Novo CA; Dayal S; Chandrakumaran K; Mohamed F; Cecil T; Moran BJ
    Eur J Surg Oncol; 2017 Feb; 43(2):388-394. PubMed ID: 27866811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
    In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.
    Shetty S; Thomas P; Ramanan B; Sharma P; Govindarajan V; Loggie B
    J Surg Res; 2013 Mar; 180(1):97-103. PubMed ID: 23199549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
    Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
    World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
    Tokunaga R; Xiu J; Johnston C; Goldberg RM; Philip PA; Seeber A; Naseem M; Lo JH; Arai H; Battaglin F; Puccini A; Berger MD; Soni S; Zhang W; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Clin Cancer Res; 2019 May; 25(10):3096-3103. PubMed ID: 30692096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
    Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
    Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
    Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
    Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
    BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.
    Gleeson EM; Feldman R; Mapow BL; Mackovick LT; Ward KM; Morano WF; Rubin RR; Bowne WB
    Am J Clin Oncol; 2018 Aug; 41(8):777-783. PubMed ID: 28263231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
    Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.